OncoCyte Corp (OCX)
2.66
-0.12
(-4.30%)
USD |
NASDAQ |
May 03, 16:00
2.69
+0.03
(+1.13%)
After-Hours: 20:00
OncoCyte Revenue (TTM): 1.503M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.503M |
| September 30, 2023 | 1.463M |
| June 30, 2023 | 1.101M |
| March 31, 2023 | 0.875M |
| December 31, 2022 | 0.958M |
| September 30, 2022 | -1.256M |
| June 30, 2022 | -0.339M |
| Date | Value |
|---|---|
| March 31, 2022 | 1.454M |
| December 31, 2021 | 2.198M |
| September 30, 2021 | 4.641M |
| June 30, 2021 | 4.212M |
| March 31, 2021 | 2.325M |
| December 31, 2020 | 1.217M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
-1.256M
Minimum
Sep 2022
4.641M
Maximum
Sep 2021
1.566M
Average
1.454M
Median
Mar 2022
Revenue (TTM) Benchmarks
| Fonar Corp | 102.42M |
| XWELL Inc | 30.11M |
| ProPhase Labs Inc | 44.38M |
| Applied DNA Sciences Inc | 8.996M |
| Veracyte Inc | 361.05M |